MENU
+Compare
TCRX
Stock ticker: NASDAQ
AS OF
Jul 22, 02:45 PM (EDT)
Price
$1.84
Change
+$0.02 (+1.09%)
Capitalization
103.56M

TCRX TScan Therapeutics Forecast, Technical & Fundamental Analysis

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer... Show more

TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for TCRX with price predictions
Jul 21, 2025

Aroon Indicator for TCRX shows an upward move is likely

TCRX's Aroon Indicator triggered a bullish signal on July 21, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 122 similar instances where the Aroon Indicator showed a similar pattern. In of the 122 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 03, 2025. You may want to consider a long position or call options on TCRX as a result. In of 68 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TCRX just turned positive on July 08, 2025. Looking at past instances where TCRX's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

TCRX moved above its 50-day moving average on July 08, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for TCRX crossed bullishly above the 50-day moving average on July 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where TCRX advanced for three days, in of 187 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TCRX moved out of overbought territory on July 15, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TCRX broke above its upper Bollinger Band on July 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.493) is normal, around the industry mean (18.131). P/E Ratio (0.000) is within average values for comparable stocks, (58.574). TCRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.444). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (50.000) is also within normal values, averaging (274.844).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly better than average price growth. TCRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
TCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

TCRX is expected to report earnings to fall 225.81% to -32 cents per share on August 13

TScan Therapeutics TCRX Stock Earnings Reports
Q2'25
Est.
$-0.33
Q1'25
Beat
by $0.54
Q4'24
Missed
by $0.01
Q3'24
Beat
by $0.06
Q2'24
Est.
$-0.28
The last earnings report on May 06 showed earnings per share of 25 cents, beating the estimate of -28 cents. With 34.01K shares outstanding, the current market capitalization sits at 103.56M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
154
Web
https://www.tscan.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SHMDF145.94N/A
N/A
Shimano Inc.
ANDC18.90N/A
N/A
Andover Bancorp, Inc.
INDFY10.76N/A
N/A
Indofood Agri Resources Ltd.
RLLWF2.36N/A
N/A
Reliance Worldwide Corp Ltd.
VRCDF0.01N/A
N/A
VERICI DX PLC

TCRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with FATE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
+0.55%
FATE - TCRX
46%
Loosely correlated
+1.77%
CRBU - TCRX
44%
Loosely correlated
+0.98%
MGNX - TCRX
44%
Loosely correlated
-4.55%
ABOS - TCRX
43%
Loosely correlated
+3.33%
EYPT - TCRX
41%
Loosely correlated
+2.33%
More